ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
9.65
-0.54 (-5.30%)
At close: Apr 28, 2026, 4:00 PM EDT
9.72
+0.07 (0.73%)
After-hours: Apr 28, 2026, 5:53 PM EDT
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 104 employees as of December 31, 2025. The number of employees decreased by 11 or -9.57% compared to the previous year.
Employees
104
Change (1Y)
-11
Growth (1Y)
-9.57%
Revenue / Employee
n/a
Profits / Employee
-$1,244,885
Market Cap
968.46M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Xeris Biopharma Holdings | 435 |
| Phathom Pharmaceuticals | 371 |
| KalVista Pharmaceuticals | 275 |
| Xencor | 260 |
| Geron | 258 |
| Omeros | 175 |
| Zenas BioPharma | 167 |
| Septerna | 130 |
ORIC News
- 11 days ago - ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 12 days ago - ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 22 days ago - ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 25 days ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - ORIC Pharmaceuticals Transcript: Study update - Transcripts
- 4 weeks ago - ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile - GlobeNewsWire
- 4 weeks ago - ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC - GlobeNewsWire
- 6 weeks ago - ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire